POM-V Prescription Required

Hypophysin LA 35 µg/ml Solution for Injection for Cattle and Pigs

Active ingredient: Carbetocin

Form

Injection

Species

Cattle Pigs

Manufacturer

Veyx-Pharma GmbH

VMD MA No.

27569/4003

What it's used for

Cows: - Uterine atony during the puerperal period - Placental retention as a consequence of uterine atony - Initiation of milk ejection in stress-induced a...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Carbetocin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Hypophysin LA 35 µg/ml Solution for Injection for Cattle and Pigs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Cows:
- Uterine atony during the puerperal period
- Placental retention as a consequence of uterine atony
- Initiation of milk ejection in stress-induced agalactia or in conditions requiring udder
emptying
Sows:
- Acceleration or restart of parturition after disruption of uterine contractions (uterine
atony or inertia) following the expulsion of at least one piglet
- Supportive therapy of mastitis-metritis-agalactia (MMA-) syndrome
- Initiation of milk ejection
- Shortening of total parturition duration as a component of synchronisation of
parturition in sows. The product may be applied to sows which have previously
been administered an appropriate PGF2 or PGF2 analogue (e.g. cloprostenol) not
prior to day 114 of pregnancy and have not started farrowing within 24 hours after
the PGF2 or PGF2 analogue injection (day 1 of pregnancy is the last day of
insemination)

For intramuscular or intravenous use.
Cows
For all indications:
6.0 – 10.0 ml/animal, corresponding to 210 – 350 µg carbetocin/animal
Sows
For shortening of total parturition duration as a part of the synchronisation of
parturition:
1.0 ml/animal, corresponding to 35 µg carbetocin/animal
For acceleration or restart of parturition after disruption of uterine contractions
(uterine atony or inertia) following the expulsion of at least one piglet:
1.0 - 2.0 ml/animal, corresponding to 35 - 70 µg carbetocin/animal
For MMA and milk ejection:
3.0 – 6.0 ml/animal, corresponding to 105 – 210 µg carbetocin/animal
The dosage requirements can be variable within the indicated limits based on the
assessment of the veterinarian.
In case of treatment for milk ejection in the cow and sow or supportive therapy in
MMA-syndrome in sow, a repeated administration is possible after 1 to 2 days. The
interval between two injections should not be shorter than 24 hours.
For all other indications stated in section 4.2 [indications] the product should be
administered once.
The rubber stopper of the vial may be safely punctured up to 25 times. Otherwise,
automatic syringe equipment, or a suitable draw-off needle, should be used for the
50 and 100 ml vials to avoid excessive puncturing of the closure.

Revised: July 2019
AN: 01071/2018
Do not administer to accelerate parturition if cervix is not opened or if there is a
mechanical cause for the delayed parturition such as physical obstruction, positional
and postural abnormalities, convulsive labour, threatened rupture of uterus, uterine
torsion, relative foetal oversize or deformities of the birth canal.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Revised: July 2019
AN: 01071/2018
In very rare cases carbetocin may have a uterotonic effect in the late pregnancy.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

The responsiveness to carbetocin of the myometrium is likely to be close to zero from
the 5
th
to the 11
th
day post-partum. Therefore, the administration of the veterinary
medicinal product during this period is likely to be inefficient and should be avoided.
If treatment with carbetocin should fail, then it is advisable to reconsider the aetiology
of the condition, specifically if hypocalcaemia could be a complicating factor.
In case of severe septic metritis, appropriate concomitant therapy should be
instigated when administering the veterinary medicinal product.

Special precautions for use in animals
None.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection uterine contractions could be induced in pregnant
women.
Pregnant women, women post-partum and breast-feeding women should not
administer this product, in order to avoid an accidental exposure.
In case of an accidental self-injection of the veterinary medicinal product in non-
pregnant women the following effects may occur: facial flushing and warmth, lower
abdominal pain. These effects usually disappear within a short span of time.
In the case of accidental self-injection, seek medical advice immediately and show
the package leaflet or the label to the physician.
Personal protective equipment consisting of disposable gloves should be worn when
handling the veterinary medicinal product.
Carbetocin may be absorbed through the skin. In case of accidental contact with the
skin, the corresponding area should be thoroughly cleaned with soap and water.
In case of contact with the eyes, they should be thoroughly rinsed with water.
People with known hypersensitivity to carbetocin or any of the excipients should
avoid contact with the veterinary medicinal product.
Women of childbearing age should administer the product with special caution.

The administration of oxytocin after the administration of the veterinary medicinal
product is un-necessary. Due to a possible intensification of the effect of oxytocin,
undesirable uterine spasms may be induced.

Excipients:
Chlorocresol 1.00 mg
For the full list of excipients, see section

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.